---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-26-000027"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:03.372346+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical prelim Q4 revenue $10.9M (+23% YoY); FY revenue $41.1M (+22% YoY); positive op cash flow

## Summary
- Preliminary Q4 2025 net revenue $10.9M, up 23% YoY; full year net revenue $41.1M, up 22% YoY.
- Ending cash balance $8.9M; positive cash flow from operations in Q4 and for full year.
- Submitted 510(k) for Freedom Infusion System for use with Phesgo, expanding into oncology.
- Company plans to release final 2025 results and 2026 guidance in early March 2026.

## SEC filing metadata
- accession: 0001161697-26-000027
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169726000027/0001161697-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169726000027/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-26-000027
- JSON: https://secwatch.observer/filing/0001161697-26-000027.json
- Plain text: https://secwatch.observer/filing/0001161697-26-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.